STXS icon

Stereotaxis

2.08 USD
-0.02
0.95%
At close Jan 17, 4:00 PM EST
After hours
2.13
+0.05
2.40%
1 day
-0.95%
5 days
1.46%
1 month
-12.24%
3 months
9.47%
6 months
2.46%
Year to date
-9.17%
1 year
13.04%
5 years
-60.08%
10 years
63.78%
0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

545% more call options, than puts

Call options by funds: $284K | Put options by funds: $44K

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

33% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

17% more funds holding

Funds holding: 71 [Q2] → 83 (+12) [Q3]

13% more capital invested

Capital invested by funds: $73.2M [Q2] → $82.4M (+$9.2M) [Q3]

0.97% less ownership

Funds ownership: 48.69% [Q2] → 47.72% (-0.97%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for STXS.

Financial journalist opinion

Neutral
GlobeNewsWire
6 days ago
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
Positive
Zacks Investment Research
1 month ago
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Neutral
GlobeNewsWire
1 month ago
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA).
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
Neutral
GlobeNewsWire
1 month ago
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL.
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Positive
Seeking Alpha
1 month ago
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
Positive
Zacks Investment Research
1 month ago
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Neutral
GlobeNewsWire
1 month ago
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference.
Stereotaxis to Participate in Piper Sandler 36th Annual Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of the Genesis RMN ® System by China's National Medical Products Administration (NMPA).
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Neutral
GlobeNewsWire
2 months ago
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
Neutral
Seeking Alpha
2 months ago
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™